Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth
BMC Medicine 2013, 11:139 (28 May 2013)
Mesenchymal stem cells (MSCs), which could be used as vehicles for anti-cancer agents owing to tumor homing properties, have different migration and recruitment capacities dependent on their lineages, suggesting that clinical characterization to ensure efficacy and safety is vital.
Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors
BMC Medicine 2013, 11:109 (23 April 2013)
Serum biomarkers identify neurofibromatosis type 1 patients at risk of malignant peripheral nerve sheath tumor development, and other markers discriminate between these patients and healthy controls, making them useful as diagnostic tools.
The sweet and sour of serological glycoprotein tumor biomarker quantification
BMC Medicine 2013, 11:31 (7 February 2013)
This article is part of a collection on
As there has been limited success in the development of glycoprotein tumor markers, Eleftherios Diamandis and colleagues review the challenges, and discuss how new technology will facilitate quantification of these biomarkers for clinical use.
Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
BMC Medicine 2012, 10:172 (27 December 2012)
Slow-cycling drug-resistant tumor cells induce a better immune response than normal tumor cells, and injecting inactivated slow-cycling cells prolongs survival of mice with cancer, indicating their promise for a cancer vaccination.